Share
Mithansh Devadiga, 5-months old has Spinal Muscular Atrophy (SMA), which affects 1 in 10,000 infants and results in progressive loss of mobility, respiratory complications, muscle weakness and atrophy, as well as challenges swallowing and eating. SMA is also the leading genetic cause of infant death worldwide.
Mithansh has the most lethal form of the disease, SMA type 1, which claims the lives of most patients by age 2. However, on this day, at this moment, this therapy, clinical trials had shown, could dramatically change the course of the disease for Mithansh. If not treated, the life span of infants with SMA Type 1 varies up to 1 or 2 years depending on the progression. Day by day his condition is worsening due to reduced muscle activity.
Zolgensma Gene Therapy is a potential cure for SMA for children below two years of age and it has to be imported from the USA. Master Mithansh needs Zolgensma gene therapy as soon as possible to save his life. Zolgensma comes at an extortionate price of INR 16 crores (USD $2.125 million) approximately excluding taxes and duties. The price of medicine is beyond my reach considering my annual income.
Donate:
Donate whatever you can with your kind heart to save Master Mithansh’s life. Please follow and share his story on social media handles and help us receive possible funds to proceed with his treatments
Spread the word:
Recently, we have been observing more and more SMA cases are visible due to developments in life-saving therapies and medicines. Spreading the word on diagnoses and about the disease could save a few more lives.
#SMA #CureSMA #spinalmascularatrophy
Please share, support & contribute as much as possible. Nothing is small or big. Every penny counts.
Thank you all in advance.
